RBCC Partner Technology Powers Better Models, Better Research

  RBCC Partner Technology Powers Better Models, Better Research

Business Wire

NOKOMIS, Fla. -- October 2, 2013

The international profile of Rainbow Coral Corp.’s (OTCBB: RBCC) partner
technology, the Bio-Assembler, continues to rise as the groundbreaking 3D cell
culturing device was featured in another new study published in a respected
scientific journal.

Recently, researchers from RBCC’s joint venture partner Nano3D Biosciences
(n3D) and Rice University published a study in the scientific journal Acta
Biomaterialia demonstrating the advantage of its technology in creating
multi-type 3D cultures that closely mimic native tissue. The group, led by
Prof. K. Jane Grande-Allen, Bioengineering, used n3D's patented Bio-Assembler
magnetic levitation technology to build a sub-physiological model of the
aortic valve that compared better to the native valve than traditional 2D

A 3D model that mimics the valve structure could serve as a foundation for
groundbreaking cardiovascular research and drug screening—which is why the
Bio-Assembler is rapidly gaining in popularity in cellular research labs
around the world.

The Bio-Assembler has been the star technology in a number of recent
high-profile scientific journal articles, including studies in Nature Reviews
Cancer, Nature Protocols and Biophysica Acta. That’s good news for RBCC, which
signed a joint venture agreement to help market the technology last year.
Widely read by researchers and scientists, these scientific journals have
already given the Bio-Assembler a big boost in name recognition among biotech

Rainbow Biosciences is dedicated to the marketing and development of new
medical and research technology innovations designed to help capture a growing
share of a booming biotech industry alongside Bristol Myers Squibb Co. (NYSE:
BMY), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and
Amgen Inc. (NASDAQ: AMGN).

For more information on RBCC’s partnership with n3D and other biotech
initiatives, please visit www.rainbowbiosciences.com/investors.html.

About Rainbow Biosciences

Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp.
(OTCBB:RBCC). The Company continually seeks out new partnerships with
biotechnology developers to deliver profitable new medical technologies and
innovations. For more information on our growth-oriented business initiatives,
please visitwww.RainbowBioSciences.com. For investment information and
performance data on the Company, please

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: This news release contains forward-looking information within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, including statements
that include the words "believes," "expects," "anticipate" or similar
expressions. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, performance
or achievements of the Company to differ materially from those expressed or
implied by such forward-looking statements. In addition, description of
anyone's past success, either financial or strategic, is no guarantee of
future success. This news release speaks as of the date first set forth above
and the Company assumes no responsibility to update the information included
herein for events occurring after the date hereof.


Rainbow Coral Corp.
Patrick Brown, 850-269-7230
President and CEO
Press spacebar to pause and continue. Press esc to stop.